Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GVB-2010
- Development stage
- Preclinical
- Lead developer
- Genvira Biosciences
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
GVB-2010 is an investigational therapeutic candidate currently in preclinical development by Genvira Biosciences for the treatment of colorectal cancer. As part of Genvira's oncology pipeline, which utilizes highly modified viral vector technologies, GVB-2010 has been evaluated in mouse model studies. While specific details regarding its molecular targets and exact modality (such as whether it is an oncolytic virus, a cancer vaccine, or a gene therapy) have not been publicly disclosed, the program represents one of the company's earlier-stage assets following its lead programs in oncolytic therapy and in vivo CAR-T cell engineering.
Beyond the preview
Go deeper on GVB-2010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GVB-2010.